Kommentar: Lundbeck skriver, modsat mange andre medicinalvirksomheder, at Covid-19 har påvirket efterspørgslen og lagernedbringelse i Q2. Et stærkt første halvår der har givet plads til en opjustering af driftsresultat.
Forventninger til resten af 2020:
- The 2020 financial guidance for revenue is maintained at DKK 17.4 – 18.0 billion based on the current assessment of the COVID-19 impact. Lundbeck has raised the guidance for core EBIT to DKK 3.9 – 4.3 billion from previously DKK 3.5 – 4.0 billion and EBIT is raised to DKK 1.8 – 2.2 billion compared to DKK 1.4 – 1.9 billion for 2020 issued previously
